Inclusion Criteria:

- Clear evidence of metastases to bone on isotope bone scan

- Histologically or cytologically confirmed metastatic Estrogen-receptor-positive (ER+)
and/or Progesterone-receptor-positive (PR+) and HER2 negative breast cancer

- Received at least one prior line of hormonal or chemo-therapy for metastatic disease

- must be post menopausal

- Recovered from toxicities related to prior treatment, except alopecia, lymphopenia,
or other non-clinically significant Adverse Events (AEs)

- Life expectancy > 3 months

- Adequate organ and marrow function

- Sexually active fertile subjects and their partners must agree to use medically
accepted methods of contraception

- Able to lie flat for up to 45 minutes for imaging studies

- Able to swallow capsules or tablets

Exclusion Criteria:

- Pregnant or breast-feeding

- Has experienced clinically-significant hematemesis or hemoptysis of > 0.5 teaspoons
of red blood, or other signs indicative of pulmonary hemorrhage within 3 months
before the first dose of study treatment

- Untreated, symptomatic or uncontrolled brain metastasis requiring current treatment
including steroids and anti-convulsants

- more than 1 prior line of chemotherapy for treatment of metastatic breast cancer

- prior treatment with fulvestrant

- Requires concomitant treatment, in therapeutic doses, with anticoagulants such as
warfarin or coumadin-related agents, thrombin or FXa inhibitors, and antiplatelet
agents (eg, clopidogrel)

- Uncontrolled or significant intercurrent illness

- Gastrointestinal disorders, particularly those associated with a high risk of
perforation or fistula formation

- Active infection requiring systemic treatment

- Serious non-healing wound/ulcer/bone fracture

- History of organ transplant

- Concurrent uncompensated hypothyroidism or thyroid dysfunction

- Previously-identified allergy or hypersensitivity to components of the study
treatment formulation

- Diagnosis of another malignancy, requiring systemic treatment, within the last 2
years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or
superficial bladder cancer